Genzyme Acquires Alfigen, Inc.
Expands its Menu and Service Offerings to Physicians and Patients
Genzyme Genetics, a business unit of Genzyme Corporation, announced that it has purchased substantially all of the assets of Alfigen, Inc., a national genetic testing provider based in Pasadena, California.
This transaction brings together two organizations committed to excellence in genetic testing. The purchase of this privately owned laboratory business allows Genzyme Genetics to expand its extensive test menu and service offerings. Alfigen offers innovative testing technologies and services, such as preimplantation genetic diagnosis, genetic counseling and continuing medical education programming.
"This acquisition provides us with an opportunity to not only leverage Alfigen's twenty years of experience within the industry, but also to utilize our existing assets and bring the combined service offerings to customers of both Alfigen and Genzyme, " says Mara Aspinall, president, Genzyme Genetics. "Like Genzyme, Alfigen's commitment to advancing science is supported by an excellent staff and we are working closely with the Alfigen team to effect a smooth transition. We are eager to continue to provide the highest quality of prenatal, oncology and other testing to physicians and patients."
"I am confident that this combination brings the highest level of quality and service to Alfigen's clients and provides opportunities for growth for Alfigen's employees", says Ahmed Alfi, CEO of Alfigen, Inc.
Genzyme Genetics intends to maintain Alfigen's Pasadena facility, and expects to fully integrate and link its operations with Genzyme's other operations. The terms of the acquisition were not disclosed.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
